S&P 500   3,841.52
DOW   31,166.94
QQQ   322.65
S&P 500   3,841.52
DOW   31,166.94
QQQ   322.65
S&P 500   3,841.52
DOW   31,166.94
QQQ   322.65
S&P 500   3,841.52
DOW   31,166.94
QQQ   322.65
Log in

MGC Pharmaceuticals Limited (MXC.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.16 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.


Overall MarketRank

0.34 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Phone61 8 6382 3390



Sales & Book Value

Annual Sales$2.08 million
Book ValueA$0.00 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive MXC News and Ratings via Email

Sign-up to receive the latest news and ratings for MXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MGC Pharmaceuticals Limited (MXC.AX) (ASX:MXC) Frequently Asked Questions

What stocks does MarketBeat like better than MGC Pharmaceuticals Limited (MXC.AX)?

Wall Street analysts have given MGC Pharmaceuticals Limited (MXC.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MGC Pharmaceuticals Limited (MXC.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were MGC Pharmaceuticals Limited (MXC.AX)'s earnings last quarter?

MGC Pharmaceuticals Limited (MXC.AX) (ASX:MXC) announced its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.
View MGC Pharmaceuticals Limited (MXC.AX)'s earnings history

Who are some of MGC Pharmaceuticals Limited (MXC.AX)'s key competitors?

What other stocks do shareholders of MGC Pharmaceuticals Limited (MXC.AX) own?

Who are MGC Pharmaceuticals Limited (MXC.AX)'s key executives?

MGC Pharmaceuticals Limited (MXC.AX)'s management team includes the following people:
  • Mr. Brett Anthony Mitchell, Exec. Chairman (Age 47, Pay $260.53k)
  • Mr. Roby Reuven Zomer, Co-Founder, CEO, MD & Exec. Director
  • Mr. Nativ Segev, Founder & Non-Exec. Director
  • Mr. Amir Polak, CTO & Head of Pharmaceutical Production
  • Ms. Sabina Suljakovic, Head of the Quality Assurance Department
  • Ms. Rachel Jelleff Kerr, Company Sec. (Leave of Absence)
  • Hugh Winters, Chief Exec. Officer of MGC Derma
  • Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB, Joint Company Sec.
  • Mr. Paul Cranney, Exec.

What is MGC Pharmaceuticals Limited (MXC.AX)'s stock symbol?

MGC Pharmaceuticals Limited (MXC.AX) trades on the ASX under the ticker symbol "MXC."

How big of a company is MGC Pharmaceuticals Limited (MXC.AX)?

MGC Pharmaceuticals Limited (MXC.AX) has a market capitalization of $0.00 and generates $2.08 million in revenue each year.

What is MGC Pharmaceuticals Limited (MXC.AX)'s official website?

The official website for MGC Pharmaceuticals Limited (MXC.AX) is www.mgcpharma.com.au.

How can I contact MGC Pharmaceuticals Limited (MXC.AX)?

The company can be reached via phone at 61 8 6382 3390.

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.